PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • Utility Of POC Xpert HIV-1 Tests For Detection-Quantification Of Complex HIV Recombinants

    Rubio-Garrido M (1), Ndarabu A (2), Reina G (3), Barquín D (4), Fernández-Alonso M (4), Carlos S (5), Holguín Á (1)

    (1) HIV-1 Molecular Epidemiology Laboratory, Microbiology and Parasitology Department, University Hospital Ramón y Cajal-IRYCIS and CIBEREsp-RITIP, Madrid, 28034, Spain.
    (2) Monkole Hospital, Kinshasa, Democratic Republic of the Congo.
    (3) Microbiology Department, Clínica Universidad de Navarra, Navarra Institute for Health Research (IdiSNA), Institute of Tropical Health, Universidad de Navarra (ISTUN), Pamplona, 31008, Spain.
    (4) Microbiology Department, Clínica Universidad de Navarra, Navarra Institute for Health Research (IdiSNA), Institute of Tropical Health, Universidad de Navarra (ISTUN), Pamplona, 31008, Spain.
    (5) Department of Preventive Medicine and Public Health, Institute of Culture and Society (ICS), Institute of Tropical Health (ISTUN), Universidad de Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, 31008, Spain.

    Sciencitific Reports 05 de ABRIL de 2019

  • Uso da bomba de balão intra-aórtico como ponte para o transplante cardíaco na Espanha

    Barge-Caballero E (1), González-Vílchez F (2), Delgado JF (3), Mirabet-Pérez S (4), González-Costello J (5), Pérez-Villa F (6), Martínez-Sellés M (7), Segovia-Cubero J (8), Hervás-Sotomayor D (9), Blasco-Peiró T (10), De la Fuente-Galán L (11), Lambert-Rodríguez JL (12), Rangel-Sousa D (13), Almenar-Bonet L (14), Garrido-Bravo IP (15), Rábago-Juan-Aracil G (16), Muñiz J (17), Crespo-Leiro MG (18(.

    (1) Servicio de Cardiología, Complejo Hospitalario Universitario A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
    (2) Servicio de Cardiología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
    (3) Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Cardiología, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
    (4) Servicio de Cardiología, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
    (5) Servicio de Cardiología, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
    (6) Servicio de Cardiología, Hospital Clinic i Provincial, Barcelona, Spain.
    (7) Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Cardiología, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Universidad Europea, Madrid, Spain.
    (8) Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
    (9) Servicio de Cirugía Cardiaca, Hospital Universitario Reina Sofía, Córdoba, Spain.
    (10) Servicio de Cardiología, Hospital Universitario Miguel Servet, Zaragoza, Spain.
    (11) Servicio de Cardiología, Hospital Clínico Universitario, Valladolid, Spain.
    (12) Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Universidad Católica San Antonio, Murcia, Spain.
    (13) Servicio de Cardiología, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
    (14) Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
    (15) Servicio de Cardiología, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
    (16) Servicio de Cirugía Cardiaca, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
    (17) Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Instituto Universitario de Ciencias de la Salud, Universidad de A Coruña, A Coruña, Spain.
    (18) Servicio de Cardiología, Complejo Hospitalario Universitario A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.

    Revista Española de Cardiología 13 de AGOSTO de 2018

  • Um grupo de alto risco, Double-Hit, de mieloma recentemente diagnosticado, identificado por análise genômica

    Walker BA (1), Mavrommatis K (2), Wardell CP (1), Ashby TC (1), Bauer M (1), Davies F (1), Rosenthal A (3), Wang H (3), Qu P (3), Hoering A (3), Samur M (4), Towfic F (5), Ortiz M (6), Flynt E (5), Yu Z (5), Yang Z (5), Rozelle D (7), Obenauer J (7), Trotter M (6(, Auclair D (8), Keats J (9), Bolli N (10), Fulciniti M (4), Szalat R (4), Moreau P (11), Durie B (12), Stewart AK (13), Goldschmidt H (14), Raab MS (14,15), Einsele H (16), Sonneveld P (17), San Miguel J (18), Lonial S (19), Jackson GH (20), Anderson KC (4), Avet-Loiseau H (21,22), Munshi N (4), Thakurta A (5), Morgan G (23).

    (1) Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
    (2) Celgene Corporation, San Francisco, CA, USA.
    (3) Cancer Research and Biostatistics, Seattle, WA, USA.
    (4) Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (5) Celgene Corporation, Summit, NJ, USA.
    (6) Celgene Institute of Translational Research Europe, Sevilla, Spain.
    (7) Rancho BioSciences, San Diego, CA, USA.
    (8) Multiple Myeloma Research Foundation, Norwalk, CT, USA.
    (9) Translational Genomics Research Institute, Phoenix, AZ, USA.
    (10) University of Milan, Milano, Italy.
    (11) University of Nantes, Nantes, France.
    (12) Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA.
    (13) Department of Hematology, Mayo Clinic, Scottsdale, AZ, USA.
    (14) Department of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
    (15) German Cancer Research Center (DKFZ), Heidelberg, Heidelberg, Germany.
    (16) Department of Internal Medicine II, Wurzburg University, Wurzburg, Germany.
    (17) Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
    (18) Clinica Universidad de Navarra, Centro Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
    (19) Winship Cancer Institute, Emory University, Atlanta, GA, USA.
    (20) Department of Haematology, Newcastle University, Newcastle, UK.
    (21) Centre de Recherche en Cancérologie de Toulouse Institut National de a Santé et de la Recherche Médicale, U1037, Toulouse, France.
    (22) L'Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire, Toulouse, France.
    (23) Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

    Leukemia 02 de JULHO de 2018

  • Um estudo europeu, observacional de administração de terapia endócrina em pacientes com um diagnóstico inicial de câncer de mama avançado positivo para receptores hormonais

    Bastiaannet E (1), Charman J (2), Johannesen TB (3), Schrodi S (4), Siesling S (5), van Eycken L (6), Walsh PM (7), Audisio RA (8), Boelens PG (1), Rubio IT (9), Jones N (10), Lewis J (10), van de Velde CJH (11).

    (1) Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
    (2) National Cancer Registration and Analysis Service, Public Health England, Birmingham, United Kingdom.
    (3) Cancer Registry of Norway, Oslo, Norway.
    (4) Munich Cancer Registry of the Munich Tumour Centre, Institute of Medical Information Processing, Biometry and Epidemiology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany.
    (5) Netherlands Cancer Registry, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.
    (6) Belgian Cancer Registry, Brussels, Belgium.
    (7) National Cancer Registry, Cork, Ireland.
    (8) University of Liverpool, St Helens Teaching Hospital, St Helens, United Kingdom.
    (9) Breast Surgical Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
    (10) AstraZeneca, Cambridge, United Kingdom.
    (11) Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands

    Clinical Breast Cancer 29 de NOVEMBRO de 2017

  • Ultrasound characteristics of endometrial cancer as defined by the International Endometrial Tumor Analysis (IETA) consensus nomenclature

    Epstein E (1), Fischerova D (2), Valentin L (3), Testa AC (4), Franchi D (5), Sladkevicius P (3), Filip F (2), Lindqvist PG (6), Mascilini F (4), Fruscio R (7), Haak LA (8), Opolskiene G (9), Pascual MA (10), Alcazar JL (11), Chiappa V (12), Guerriero S (13), Carlson J (14), Van Holsbeke C (15), Leone FPG (16), De Moor B (17), Bourne T (18,19), van Calster B (19), Installe A (17), Timmerman D (19,20), Verbakel JY (19,21), Van den Bosch T (20). (1) Department of Clinical Science and Education, Södersjukhuset and Department of Women's and Children's health Karolinska Institutet, Stockholm, Sweden.
    (2) Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
    (3) Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Lund University, Sweden.
    (4) Department of Gynecological Oncology, Catholic University of Sacred Heart, Rome, Italy.
    (5) Department of Gynecological Oncology, Milan, Italy.
    (6) Department of Obstetrics and Gynecology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
    (7) Clinic of Obstetrics and Gynecology, University of Milan Bicocca, San Gerardo Hospital, Monza, Italy.
    (8) Institute for the Care of Mother and Child, Prague, Czech Republic and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
    (9) Center of Obstetrics and Gynecology, Vilnius University Hospital, Santariskiu clinic, Lithuania.
    (10) Department of Obstetrics, Gynecology, and Reproduction, Hospital Universitario Dexeus, Barcelona, Spain.
    (11) Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, Pamplona, Spain.
    (12) Department of Obstetrics and Gynecology, National Cancer Institute, Milan, Italy.
    (13) Department of Obstetrics and Gynecology, University of Cagliari, Policlinico Universitario Duilio Casula, Monserrato, Cagliari, Italy.
    (14) Department of Pathology, Karolinska University Hospital, Stockholm, Sweden.
    (15) Department of Obstetrics and Gynecology, Ziekenhuis Oost-Limburg, Genk, Belgium.
    (16) Department of Obstetrics and Gynecology, Clinical Sciences Institute, L. Sacco, Milan, Italy.
    (17) Department of Electrical Engineering, ESAT-SCD, STADIUS Center for Dynamical Systems, Signal Processing and Data Analysis, KU Leuven, and imec, Leuven, Belgium.
    (18) Department of Obstetrics and Gynaecology, Queen Charlottes and Chelsea Hospital, Imperial College London, UK.
    (19) Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
    (20) Department of Obstetrics and Gynecology, University Hospital Leuven, Leuven, Belgium.
    (21) Nuffield Department of Primary Care Health Sciences, University of Oxford, UK.

    Ultrasound in Obstetrics & Gynecology 25 de SETEMBRO de 2017

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra